MedTrace Logo

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

NCT02082691 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2014-03-10

No results posted yet for this study

Summary

Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study. Patient's cancer responded well to receiving G-202 in the main study and will receive G-202 at the same dose given in the main study.

Conditions

Interventions

DRUG

G-202

Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.

Sponsors & Collaborators

  • GenSpera, Inc.

    collaborator INDUSTRY

  • Devalingam Mahalingam

    lead OTHER

Principal Investigators

  • Devalingam Mahalingam, MD · University of Texas Health Science Center San Antonio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02082691 on ClinicalTrials.gov